Assets
Our Assets
Trustlife offers a robust portfolio of assets that span the entire drug discovery pipeline, from target identification to hit discovery and preclinical development. With a strong focus on oncology and complex diseases, these assets combine advanced AI-driven platforms with a proprietary pipeline of drug candidates developed in Trustlife's own R&D laboratories.
Drug Candidates
The asset portfolio includes 14 proprietary molecules targeting oncology and complex diseases. Discovered using Trustlife AI and developed entirely in Trustlife's state-of-the-art R&D laboratories, these drug candidates are the result of rigorous scientific methodologies and innovative research approaches, offering new possibilities for effective treatments and improved patient outcomes.
By combining cutting-edge AI assets with a focused and innovative drug candidate pipeline, Trustlife delivers integrated solutions that drive medical research forward and address critical drug discovery challenges.
AI Assets
The Trustlife AI platform integrates essential technologies to support every critical step of the drug discovery process:
T-TARGET
Target Identification
Data-driven solution for identifying high-potential drug targets using systems biology and AI analytics.
T-ECO
Microbial Analysis
Comprehensive microbiome atlas that connects microbial insights with therapeutic opportunities.
T-DRUG
Drug Repositioning
Advanced hit discovery engine that streamlines the identification and validation of promising drug candidates.
T-CHAT
AI Assistant
Large Language Model to extract, refine and prioritize data from T-TARGET, T-ECO and T-DRUG.
Digital TwinNEW
Dynamic Whole-Body Modelling
Digital Twin models the human body as a dynamic, interconnected system, combining AI, multi-omics, and systems biology.
Mechanistic simulation • Toxicity Assessment • Efficacy Projections
Multi-omics Integration• Host–Microbiome Effects • Dynamic Data
Decision-ready insights for drug discovery and personalized medicine.